Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05573490
Other study ID # 14594
Secondary ID AARG-22-9269401K
Status Recruiting
Phase N/A
First received
Last updated
Start date January 11, 2024
Est. completion date June 2028

Study information

Verified date March 2024
Source Indiana University
Contact Dustin B Hammers, PhD
Phone 3179638557
Email hammersd@iu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease. It is hypothesized that participants in the experimental training condition will perform better on outcomes related to cognition, functioning, and mood at follow-up compared to participants assigned to the active control condition.


Description:

This study aims to generate preliminary data regarding the efficacy of a combined cognitive-training and Tai Chi- Qi Gong exercise lifestyle intervention in participants diagnosed with Early-Onset Alzheimer's Disease (EOAD). Participants will complete a series of cognitive, functional, and mood assessments at a remotely-assessed baseline visit, and then be randomized into one of two conditions: (1) Computerized Cognitive Training + Tai Chi Exercise or (2) Active Control. Outcome measures will be repeated immediately Post-Treatment and at 6-months post-treatment Follow-Up. Specific Aim 1 will examine the feasibility of this lifestyle intervention and outcome assessments when applied to participants with EOAD. Specific Aim 2 will investigate if this lifestyle intervention improves short- and long-term cognition, functioning, and mood. Specific Aim 3 will be exploratory to assess whether individual differences in training or clinical/ demographic characteristics moderate the degree of benefit from this intervention; owing to sample size limitations in this feasibility study, focus of this latter aim will be on determining effect sizes and sample-size magnitude needed for future work.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2028
Est. primary completion date June 2028
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Enrolled in the Longitudinal Early-Onset AD Study (LEADS) parent study, and being classified via LEADS consensus criteria as having amyloid-positive Early Onset Alzheimer's Disease - Aged 40-64 years at the time of enrollment into LEADS - Fluent in English - In good general health and absent another neurological disorder - Have a knowledgeable informant. - Have had a Clinical Dementia Rating scale of 0.5 to 1.0 at the time of enrollment into LEADS - Have sufficient vision, hearing, comprehension, and manual dexterity to participate in the testing and training program Exclusion Criteria: • Have access to the internet (e.g., home, family, public library, etc.) for less than 4 hours per week

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cognitive Training
Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
Behavioral:
Tai Chi- Qi Gong
Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
Device:
Brain Games
Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
Behavioral:
Stretching
Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.

Locations

Country Name City State
United States Indiana University Indianapolis Indiana

Sponsors (5)

Lead Sponsor Collaborator
Indiana University Alzheimer's Association, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Tai Chi Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance on CANTAB Connect computerized Memory Composite immediately post-intervention, after controlling for baseline performance CANTAB Connect computerized Memory Composite was selected for its remote assessment of memory, with validation in Alzheimer's Disease samples. This composite will be calculated from Paired Associates Learning, Pattern Recognition Memory, and Verbal Paired Associates subtests, with higher scores reflected better performance. 15-Week Post-Intervention Follow-up
Primary Performance on CANTAB Connect computerized Executive Composite immediately post-intervention, after controlling for baseline performance CANTAB Connect computerized Executive Composite was selected for its remote assessment of executive functioning, with validation in Alzheimer's Disease samples. This composite will be calculated from Stockings of Cambridge, Spatial Working Memory, Rapid Visual Processing, and Match To Sample subtests, with higher scores reflected better performance. 15-Week Post-Intervention Follow-up
Primary Performance on CANTAB Connect computerized Memory Composite 26 weeks after intervention, after controlling for baseline performance CANTAB Connect computerized Memory Composite was selected for its remote assessment of memory, with validation in Alzheimer's Disease samples. This composite will be calculated from Paired Associates Learning, Pattern Recognition Memory, and Verbal Paired Associates subtests, with higher scores reflected better performance. 40-Week Post-Intervention Follow-up
Primary Performance on CANTAB Connect computerized Executive Composite 26 weeks after intervention, after controlling for baseline performance CANTAB Connect computerized Executive Composite was selected for its remote assessment of executive functioning, with validation in Alzheimer's Disease samples. This composite will be calculated from Stockings of Cambridge, Spatial Working Memory, Rapid Visual Processing, and Match To Sample subtests, with higher scores reflected better performance. 40-Week Post-Intervention Follow-up
Secondary Benefit from Cognitive Training using Cognitive Self-Report Questionnaire immediately post-intervention, after controlling for baseline performance Cognitive Self-Report Questionnaire is a 25-item self-report questionnaire of subjective cognitive difficulties. Scores range from 0-125, with higher scores denoting greater cognitive symptoms. This measure has been used in a variety of studies examining benefit from cognitive training. 15-Week Post-Intervention Follow-up
Secondary Benefit from Cognitive Training using Cognitive Self-Report Questionnaire 26 weeks after intervention, after controlling for baseline performance Cognitive Self-Report Questionnaire is a 25-item self-report questionnaire of subjective cognitive difficulties. Scores range from 0-125, with higher scores denoting greater cognitive symptoms. This measure has been used in a variety of studies examining benefit from cognitive training. 40-Week Post-Intervention Follow-up
Secondary Performance on scales of functioning immediately post-intervention, after controlling for baseline performance The Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory is an informant-based rating scale that assesses the participant's ability to perform a variety of activities of daily living over the past four weeks, and has been shown to discriminate between healthy elderly controls and those with mild Alzheimer's disease. Scores range from 0-78, with higher scores denoting better functional ability. 15-Week Post-Intervention Follow-up
Secondary Performance on scales of functioning 26 weeks after intervention, after controlling for baseline performance The Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory is an informant-based rating scale that assesses the participant's ability to perform a variety of activities of daily living over the past four weeks, and has been shown to discriminate between healthy elderly controls and those with mild Alzheimer's disease. Scores range from 0-78, with higher scores denoting better functional ability. 40-Week Post-Intervention Follow-up
Secondary Self-reported depression immediately post-intervention, after controlling for baseline performance 21-item Beck Depression Inventory-2 was used as a measure of self-reported depression. Scores range from 0-63, with higher scores denoting greater self-reported depression symptoms. 15-Week Post-Intervention Follow-up
Secondary Self-reported depression 26 weeks after intervention, after controlling for baseline performance 21-item Beck Depression Inventory-2 was used as a measure of self-reported depression. Scores range from 0-63, with higher scores denoting greater self-reported depression symptoms. 40-Week Post-Intervention Follow-up
Secondary Self-reported quality of life immediately post-intervention, after controlling for baseline performance 13-item Quality of Life- Alzheimer's Disease scale was used as a measure of self-reported quality of life. Scores range from 13-52, with higher scores denoting greater self-reported quality of life. 15-Week Post-Intervention Follow-up
Secondary Self-reported quality of life 26 weeks after intervention, after controlling for baseline performance 13-item Quality of Life- Alzheimer's Disease scale was used as a measure of self-reported quality of life. Scores range from 13-52, with higher scores denoting greater self-reported quality of life. 40-Week Post-Intervention Follow-up
Secondary Self-reported stress immediately post-intervention, after controlling for baseline performance 4-item Perceived Stress Scale was used as a measure of self-reported stress. Scores range from 0-16, with higher scores denoting greater stress. 15-Week Post-Intervention Follow-up
Secondary Self-reported stress 26 weeks after intervention, after controlling for baseline performance 4-item Perceived Stress Scale was used as a measure of self-reported stress. Scores range from 0-16, with higher scores denoting greater stress. 40-Week Post-Intervention Follow-up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03625401 - Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease Phase 2
Recruiting NCT05983575 - A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease Phase 3
Completed NCT05989087 - The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Recruiting NCT06080659 - Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity N/A
Not yet recruiting NCT06099587 - MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease N/A
Not yet recruiting NCT05604183 - Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease N/A
Withdrawn NCT03514875 - Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients N/A
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Completed NCT03706885 - Efavirenz for Patients With Alzheimer's Disease Phase 1
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Not yet recruiting NCT05006599 - SNIFF - 3-Week Aptar CPS Device Phase 2
Recruiting NCT02740634 - Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study N/A
Active, not recruiting NCT03069391 - The Interactive Physical and Cognitive Exercise System N/A
Recruiting NCT04701957 - The Ketogenic Diet for Alzheimer's Disease N/A
Recruiting NCT06268886 - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease Phase 2
Recruiting NCT04100889 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Recruiting NCT04656860 - Juice Plus Supplement Clinical Trial N/A
Recruiting NCT05315895 - The Dampness Syndrome of Chinese Medicine Cohort Study
Recruiting NCT04916964 - Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial) N/A
Recruiting NCT04804618 - Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease